Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions

Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions

Background: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Ian D. Pavord, MD, Michael E. Wechsler, MD, William W. Busse, MD, Christian Domingo, MD, Changming Xia, PhD, Rebecca Gall, MD, Nami Pandit-Abid, PharmD, Juby A. Jacob-Nara, MD, DHSc, Amr Radwan, MBBChir, Paul J. Rowe, MD, Yamo Deniz, MD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Dupilumab
asthma
Feno
asthma exacerbation
lung function
asthma control
Online Access:http://www.sciencedirect.com/science/article/pii/S277282932500075X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S277282932500075X

Similar Items